Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
62.9M
-
Number of holders
-
51
-
Total 13F shares, excl. options
-
18.3M
-
Shares change
-
+18.3M
-
Total reported value, excl. options
-
$200M
-
Value change
-
+$200M
-
Number of buys
-
50
-
Price
-
$10.97
Significant Holders of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) as of Q4 2021
51 filings reported holding PYXS - Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share as of Q4 2021.
Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.3M shares
of 62.9M outstanding shares and own 29.14% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (2.28M shares), RTW INVESTMENTS, LP (2.12M shares), PERCEPTIVE ADVISORS LLC (1.94M shares), BVF INC/IL (1.79M shares), CITADEL ADVISORS LLC (1.52M shares), JANUS HENDERSON GROUP PLC (1.47M shares), Laurion Capital Management LP (1.16M shares), HHLR ADVISORS, LTD. (764K shares), ACUTA CAPITAL PARTNERS, LLC (678K shares), and Cormorant Asset Management, LP (669K shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.